Video

Importance of appropriate patient selection for PARP inhibitors in prostate cancer

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Atish D. Choudhury, MD, PhD, discusses the significance of optimizing patient selection when using PARP inhibitors for prostate cancer. Using these agents in patients unlikely to benefit adds unnecessary pill, toxicity, and financial burdens to the recipient, explains Choudhury. He notes the importance of finding biomarkers to facilitate appropriate patient selection.

      Choudhury is a medical oncologist and clinical/translational investigator within the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, and currently serves as Chair of the Gelb Center for Translational Research.

      © 2025 MJH Life Sciences

      All rights reserved.